RBM22P4

Across TCGA pan-cancer cohorts, RBM22P4 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated RBM22P4 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RBM22P4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM22P4 expression acts as an unfavorable survival marker, although some lineages such as ESCA and LUAD show a favorable association.

KIRC, BLCA, and CESC are the cancer types where RBM22P4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Quartile	All	0.731	0.819	.004	77	view →
BLCA	OS	Tertile	All	0.583	0.749	.003	63	view →
CESC	DFS	Tertile	III,IV	0.284	0.670	.003	60	view →
THYM	DFS	Tertile	All	0.625	0.935	.001	36	view →
OV	OS	Tertile	IV	0.545	0.798	.017	24	view →
ACC	DFS	Tertile	All	0.150	0.579	.008	21	view →
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	18	view →
SKCM	OS	Tertile	III,IV	0.564	0.739	.004	14	view →
ESCA	DFS	Median	III,IV	0.424	0.248	.025	5	view →
THCA	DFS	Tertile	III,IV	0.476	0.746	.023	3	view →
LUAD	DFS	Tertile	All	0.790	0.648	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RBM22P4–KIRC (DFS)

Open the KIRC breakdown →